CT52923

CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer[1].

Product Specifications

CAS Number

[205256-55-9]

UNSPSC

12352005

Target

PDGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ct52923.html

Concentration

10mM

Purity

98.58

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

S=C(N1CCN(CC1)C2=C3C=C(OC)C(OC)=CC3=NC=N2)NCC4=CC=C5OCOC5=C4

Molecular Formula

C23H25N5O4S

Molecular Weight

467.54

References & Citations

[1]J C Yu, et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther. 2001 Sep;298 (3) :1172-8.